Contraceptive Progestogens and Incident Meningioma - Takeaways - MDSpire

Contraceptive Progestogens and Incident Meningioma

  • By

  • Nicklas Hasselblad Lundstrøm

  • Mette Hjorslev Knudgaard

  • Michael Skaarup Pedersen

  • Marie Louise Schougaard Christiansen

  • Charlotte Wessel Skovlund

  • July 2, 2026

  • 0 min

Share

  • 1

    Meningioma is the most common intracranial tumor in adults, accounting for 38% to 42% of primary CNS tumors.

  • 2

    The incidence of meningioma is higher in women, with rates of 13.90 per 100,000 for women compared to 6.02 for men in the U.S.

  • 3

    Biological evidence suggests a hormonal role in meningioma development, supported by the presence of progesterone receptors in up to 87% of cases.

  • 4

    Several high-dose progestogens have been linked to an increased risk of meningioma, but evidence for hormonal contraceptives remains conflicting.

  • 5

    This study is the first to systematically assess meningioma risk by hormonal composition across all contraceptive types in females.

Original Source(s)

Contraceptive Progestogens and Incident Meningioma

  • by Nicklas Hasselblad Lundstrøm, Mette Hjorslev Knudgaard, Michael Skaarup Pedersen, Marie Louise Schougaard Christiansen, Charlotte Wessel Skovlund

  • July 2, 2026

Related Content

2026 ASCO Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates

  • July 2, 2026

  • 1 min
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min
Factors associated with relapse/progression in pediatric trunk and extremity rhabdomyosarcoma